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Every innovation in medicine is met with a mixture of 
excitement, expectation and a certain degree of apprehension. 
Nowhere is this more apparent than in the field of cell-
based therapy, i.e. the application of cells to patients, locally 
or systemically, for therapeutic purposes. Excitement and 
expectation are generated by the many preclinical and early 
clinical studies that continue to reveal the enormous potential 
of regenerative medicine. The recent successful implantation 
of a large airway, engineered ex vivo from a donor trachea, into 
a patient as a replacement for a stenosed left main bronchus 
(post-tuberculosis), is a case in point.1 Likewise, reports of 
dramatic functional improvement in children with cerebral 
palsy treated with autologous cord-blood stem cells at Duke 
University warrant our serious consideration.2 And this is just 
the beginning. It is believed that cell-based therapy will have a 
significant positive impact on virtually every organ system in 
the body, and that the extent of this impact is limited only by 
the limits of our scientific creativity. 
However, these innovations come with numerous complex 
and challenging moral and ethical issues, including for 
example those surrounding embryonic stem cells, stem 
cell banking and the ethics of cloning (therapeutic versus 
reproductive). And of course, patient safety needs to be 
ensured.
In order to ensure that cost-effective therapeutic benefit and 
patient safety are well balanced, many elements need to be in 
place. Among these is an appropriate regulatory environment 
in which all activities involving cell therapy are governed by 
an appropriate set of rules and guidelines. Several important 
reasons follow: 
1.    Work involving material that will be (re)introduced into 
patients must be conducted under strictly controlled 
and accredited conditions of sterility to ensure that the 
unintended transfer into patients of harmful material 
(infectious and otherwise) is avoided. 
2.    Preclinical studies and well-controlled clinical trials need 
to have been conducted before introduction of cells into 
patients to ensure that the purported therapeutic effect is 
real and that there are no serious side-effects.
3.    The absence of regulations permits (and even encourages) 
the emergence of medically unsound and unethical 
practices that may be associated with the exploitation of 
emotionally vulnerable patients.
4.    The absence of regulations dissuades the transfer of 
intellectual property and foreign investment into South 
Africa because of the fear of an unknown legislative 
environment that may impact negatively on activities that 
have taken considerable time and resources to establish, 
when the regulations do come into play. 
With regard to human tissues in general, and stem cells in 
particular, South Africa is currently operating in a regulatory 
vacuum in which the rules and guidelines are fragmentary. For 
example, those that dictate how we should conduct research 
on stem cells are incomplete. Likewise, issues relating to 
whether or not stem cells should be stored, and whether or not 
businesses should operate on a ‘for-profit’ or ‘not-for-profit’ 
basis, have not been fully debated. Nor have the complex 
issues surrounding the creation and use of embryonic stem 
cells or cloning. The current situation is therefore critically 
fragile and specific legislation is sorely lacking. 
The National Health Act (No. 61 of 2003) (NHA), which 
replaced an outdated set of acts previously in force, was 
published 6 years ago. Chapter 8 of the NHA, which deals 
with the ‘Control of use of blood, blood products, tissue and 
gametes in humans’, has to date not been promulgated (with 
the exception of Section 53, which deals with the establishment 
of a blood transfusion service, and which was enacted on 30 
June 2008). This means that we have to fall back on the Human 
Tissue Act (No. 65 of 1983), which was published at a time 
at which many of the complex and controversial issues that 
require carefully balanced rules and guidelines were not yet 
part of the scientific landscape.
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No specific regulations dealing with activities involving 
human stem cells have yet been formalised by the Department 
of Health to support the relevant Act(s) addressing this subject. 
It must be noted, however, that over the last few years the 
Department has published several sets of draft regulations 
dealing with human tissues including stem cells, gametes, in 
vitro fertilisation, DNA, etc. However, none of these regulations 
are currently in force. 
The absence of regulations exposes South Africans to several 
potential problems. First, the absence of clear guidelines that 
ensure patient safety impacts negatively on patient outcomes. 
In addition to the more obvious issue of infection (transfer 
of infectious agents in transplanted material), the long-term 
consequences that could result from transplantation of material, 
the biological activity of which has not been adequately 
studied, need to be borne in mind. A recent report on a boy 
with ataxia telangectasia who developed a multifocal brain 
tumour following treatment with human fetal neural stem cells 
(administered via intracerebellar and intrathecal injection) is a 
case in point.3
Second, the absence of a regulatory framework creates 
opportunities for the proliferation of undesirable practices 
and creates opportunities for individuals to move freely into 
areas and practices that are medically untested or frankly 
unsound. In a recent survey of 8 South African patients who 
received ‘stem cell’ therapy for spinal cord injury (one of 
whom subsequently developed the locked-in syndrome), the 
following facts emerged: (i) 5 of the 8 patients went overseas 
and 1 received cells from Germany in South Africa, at an 
average cost of R122 500 per treatment (excluding travel 
and accommodation costs for those who went overseas); (ii) 
4 patients received rabbit stem cells, 1 received autologous 
stem cells, 1 received cells of unknown origin and the 2 that 
remained in South Africa received sheep stem cells; and (iii) 
the stem cells were injected subcutaneously, intramuscularly, 
intravenously, via lumbar puncture or into the subdural 
space during spinal surgery (Skeen and Pepper – upublished 
paper presented at the 7th South African Symposium on 
Haematopoietic Stem Cell Transplantation, Johannesburg, 30 - 
31 January 2009). The lack of regulations means that there is no 
check in place to prevent activities of this sort. 
Third, local organisations and businesses wishing to enter 
the cell therapy field do so without knowing whether their 
operations will be impacted on negatively by legislation once 
this is formalised. Furthermore, the absence of regulations 
results in a lack of investment into activities associated directly 
or indirectly with cell therapy. This is because an unstable 
regulatory environment may have negative consequences on 
investment into the field with the publication of regulations 
that may be restrictive. Foreign investors who may wish to 
consider investing into South African cell therapy businesses 
will be dissuaded from so doing because they have no way of 
knowing whether, when the regulations do come into effect, 
they will impact negatively on the activities into which the 
investors have put their money.
The enormous potential benefits that cell-based therapy 
has to offer to human health – and South African patients are 
no exception – are undisputed. The facilitation of research in 
cell-based therapy and the implementation of such therapies 
are therefore highly desirable. In order for this to occur, an 
appropriate regulatory environment is required. Without 
this, South Africans not only run the risk of being denied 
the fruits of cutting-edge research, but will also be exposed 
to unethical practices and financial exploitation (especially 
those who are emotionally vulnerable). From an economic 
point of view, and specifically from a biotech point of view, 
the absence of a regulatory environment that should provide 
comfort for potential investors is likely to put South Africa 
light-years behind in the development and use of new cell 
therapy products. The lack of movement in the development 
of appropriate legislation and the precarious situation that 
our country finds itself in by perpetuating an unregulated 
environment, point to an urgent need for open consultation 
between all relevant stakeholders. 
Any discussion on cell therapy needs to take the following 
into consideration. An important distinction needs to be 
made between activities that involve altruistic donation of 
human material and those that result in commercial gain. 
Any commercial activity directly involving human material 
(including stem cells) that is provided on an altruistic basis 
by a voluntary donor should be run on a not-for-profit basis 
with publicly accessible accountability of how resources are 
managed. Other activities that involve human stem cells 
directly or indirectly and that are not based on the principle 
of an altruistic donation should be permitted to run on a for-
profit basis. It is important to note that in accordance with 
the National Health Act, stem cells may not be sold or traded 
privately. Furthermore, payment in respect of the acquisition, 
supply, importation or export of stem cells may only be 
received by an authorised institution.
The development of relevant regulations to support the 
Human Tissues Act lies within the jurisdiction of the national 
Department of Health. Given the huge burden that infectious 
diseases place on our national resources (financial and 
human), it is understandable that priorities within the National 
Department of Health may not lie with the topic of this article. 
Chapter 8 of the NHA and the regulations pertaining thereto 
have been written and published, but not yet enacted. Given 
the long time delays between publication of the initial versions 
(upon which formal comments/submissions have already 
been made) and the present time, during which (i) the diverse 
stakeholders have had a chance to grow in their understanding 
of the cell-therapy field, and (ii) significant advances and 
new challenges have arisen, fresh debate is needed before re-
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activating the legislative machine. Only after this has taken 
place will it be appropriate to revisit and revise the current 
documents. Once this has been done, it is sincerely hoped that 
the passage into formal legislation will be expedited. 
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